Our Company

The determination to transform lives

It’s all in our name: Volition means to have determination and a purpose.

volition-team

It’s all in our name: Volition means to have determination and a purpose

From penicillin to vaccines to genome editing, all the greatest scientiﬁc discoveries have something in common: the determination to transform lives on a global scale, no matter what hurdles block the path of progress.

That’s why we named ourselves Volition, to honor the central importance and absolute focus of that purpose and determination in revolutionizing the way disease is diagnosed and monitored.

Our Company

Advancing the science of epigenetics

About Volition

Volition is a multi-national epigenetic company focused on advancing the science of epigenetics. We are dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.

Through our subsidiaries, we are developing and commercializing simple, easy to use, cost-effective blood tests to help diagnose and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis.

Watch our video Our Team

Our values

We are determined to revolutionize the way disease is diagnosed and monitored. Here are the values that drive us every day.

We believe in ourselves

We believe wholeheartedly in the power of our technology, our products, and our people. Nucleosomics™ technology has the potential to play an important role in the ﬁght to save lives and improve outcomes worldwide. This belief and passion are what drive and sustain us and everyone who joins us.

We act with humility

We are inspired every day by the potential of what we do and what we can achieve together. Our horizon is continuously expanding beyond cancer to a whole range of life-altering diseases, beyond humans to animals, to ﬁnd and address a host of unmet clinical needs, always with the patient at the forefront of our minds.

We are in this together, for everyone

The science of what we do is detailed and complex, but Nu.Q^® itself is not. A simple, routine blood test, like a blood sugar or cholesterol test, our goal is that Nu.Q^® will be aﬀordable and available to all. And this is the essence of who we are. We are in this together, for everyone.

We dare to be different

What we do and the way we do it is completely unique. We dare to challenge the status quo to advance the science of epigenetics and improve outcomes for people and animals worldwide. We seek to change the world by allowing physicians to use the hidden information in chromosomes to detect disease earlier, monitor it more eﬀectively and help improve outcomes.

We strive to be the best

Our team are leading experts in epigenetics. For over a decade we have evolved and mastered our understanding of nucleosomes. We have developed and reﬁned our technology to be what we believe to be the best-in-class in the diagnostics industry. Everything we do, we do to the very best of our ability.

Working together

In collaboration with.

Cultivating successful, ongoing relationships with stakeholders worldwide has been fundamental to Volition’s development. We have fostered ties with leading academic institutions, clinical centers of excellence, multi-national pharmaceutical companies and funders from across the globe.

Our story.

Volition was established in 2010. Our co-founding scientists, Jake Micallef and Mark Eccleston joined forces with our Group CEO, Cameron Reynolds, with the aim of transforming cancer diagnostics from expensive, invasive, and often unpleasant procedures to something as fast and accessible as cholesterol or pregnancy testing.

The company has grown from a single two-meter lab bench at the University of Namur in Belgium to a purpose-built 20,000 square feet lab in Gembloux, Belgium, an Innovation Lab in California, and offices in California, London, Singapore and Nevada.

In 2015 the company was listed on the New York Stock Exchange (VNRX). We now have a team of over 80 dedicated staff, spanning a wide range of disciplines; all united in our mission to improve outcomes for patients.

Volition 230619

Volition Corporate Video

Media

Our latest news

VolitionRX Limited: Outlines broad strategy to become the “N…

VolitionRX Limited: Revolutionizing the diagnosis and monito…

VolitionRx Limited Announces Full Fiscal Year 2024 Financial…

Volition Announces Two Poster Presentations at ESMO’s Europe…

Volition to Host Virtual Investor Event on Nu.Q® Cancer, “A …

VolitionRx Announces Pricing of up to $2.3 Million Registere…

VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings …

Volition’s Nu.Q® Cancer Diagnostics Test Aims To Disrupt the…

Volition Introduces Nu.Q® Cancer Blood Test in New Industry …

Volition Proudly Sponsors the 44th ISICEM Congress

Volition Signs first ever Nu.Q® Vet Cancer Test Automation A…

Volition Announces First Patient Enrolled in NTU Hospital’s …